The U.S. Food and Drug Administration (USFDA) has suspended the biologics license of Ixchiq (Chikungunya Vaccine, Live), ...

Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...

FDA suspends Ixchiq license, raising regulatory risks for Valneva. Key vaccines anchor revenue, but valuation concerns emerge ...

Investing.com - Jefferies has reduced its price target on Valneva SE (NASDAQ:VALN) to $14.00 from $18.00 while maintaining a Buy rating on the stock. Currently trading at $9.13, Valneva has shown ...

The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of Ixchiq in the United States. The suspension follows the US FDA’s decision on August 6, 20251 ...

The United States Food and Drug Administration (FDA) has suspended the licence of one of the two chikungunya vaccines ...

By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is ...

Worrisome new signals caused the U.S. FDA – which earlier this month OK’d revised labeling for Valneva SE’s chikungunya virus ...

US health authorities have suspended the licence for the Ixchiq vaccine against the chikungunya virus following reports of “serious adverse events”, the drug’s French maker said Monday.

The decision to suspend the Ixchiq vaccine comes as public health experts warn the mosquito-spread virus could pose a future pandemic threat.

The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker ...

Analysts on Monday expressed divergent opinions on vaccine company Valneva SE (VALN) after the firm said that the United ...